One To Watch

Argenx

Company Overview

A global immunology company commercializing efgartigimod, the first approved FcRn blocker, across multiple severe autoimmune diseases, while deploying a $5.2 billion cash position to build a ten-molecule pipeline. argenx SE (Euronext & Nasdaq: ARGX) generated $2.8 billion in product net sales in the first half of 2026, up from $1.7 billion a year earlier, on the back of its VYVGART franchise: generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) globally, plus primary immune thrombocytopenia (ITP) in Japan.

The company's pending $2.2 billion acquisition of Forte Biosciences, announced July 27, 2026, would add a mechanistically distinct asset alongside that FcRn franchise. The transaction has not closed.

Headquarters and Global Presence

argenx is headquartered in Amsterdam, the Netherlands, and was originally founded in Ghent, Belgium. The company trades on Euronext and on Nasdaq under the ticker ARGX, and maintains a commercial presence across the United States, Japan, and key European markets including Germany, France, Spain, Italy, and the United Kingdom.

Regulatory reach widened through 2024 and 2025. Japan's Ministry of Health, Labor and Welfare approved the subcutaneous formulation Vyvdura in generalized myasthenia gravis in June 2024 and in CIDP in December 2024. The European Commission cleared Vyvgart in CIDP in June 2025, and the UK MHRA granted a new Vyvgart indication in December 2025.

Founding and History

argenx was founded in 2008 in Ghent, Belgium by Tim Van Hauwermeiren, a former executive at Ablynx, together with colleagues Hans de Haard and Torsten Dreier. The company listed on the Brussels Stock Exchange and Nasdaq, joining the BEL 20 index in June 2018. Its first FDA approval came in 2021 for VYVGART in myasthenia gravis, and a prefilled syringe formulation was approved in April 2025.

The company has since grown into a fully commercial, profitable enterprise, with full-year 2025 product net sales of approximately $4.15 billion, a 90% year-over-year increase.

Therapy Areas and Focus

argenx is focused exclusively on severe autoimmune diseases, with its current commercial footprint spanning neuromuscular and inflammatory conditions: generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and primary immune thrombocytopenia in Japan. The late-stage pipeline extends into myositis, multifocal motor neuropathy, Sjogren's disease, and congenital myasthenic syndromes.

The pending addition of Forte Biosciences' FB102 would open dermatological and gastrointestinal autoimmune indications: vitiligo, alopecia areata, and celiac disease. That would be a meaningful broadening of the therapeutic footprint, and it depends on the deal closing.

Technology Platforms and Modalities

argenx built its franchise on FcRn blockade: efgartigimod binds the neonatal Fc receptor to accelerate clearance of pathogenic IgG antibodies, removing the immune mediators that drive disease rather than targeting a single downstream effector. The company describes VYVGART as a "pipeline in a product," reflecting its applicability across dozens of IgG-mediated conditions.

Beyond FcRn, the pipeline now spans a complement inhibitor (empasiprubart targeting C2), a MuSK agonist antibody (adimanebart), an IgA-targeting antibody (ARGX-121), and next-generation FcRn candidates engineered for extended half-life. The Immunology Innovation Program (IIP) generated four new candidates in 2025, with three more expected to enter Phase I in 2026.

Key Pipeline and Programs

Efgartigimod (VYVGART/VYVGART Hytrulo) is the company's approved FcRn blocker, already commercialized in gMG and CIDP globally. Registrational Phase III data from the ALKIVIA study in myositis are expected in Q3 2026, while the Phase III UNITY trial in Sjogren's disease is expected to read out in the second half of 2027. ADAPT OCULUS data, presented at AAN 2026, showed VYVGART became the first biologic to meet its primary endpoint in ocular myasthenia gravis, and a supplemental Biologics License Application submission is planned.

Empasiprubart is a first-in-class anti-C2 antibody in Phase III for both multifocal motor neuropathy (EMPASSION study, topline results expected Q4 2026) and CIDP, with a Phase II study also underway in delayed graft function. ARGX-213 is a next-generation FcRn antibody engineered for sustained IgG reduction and is Phase III ready.

Adimanebart (ARGX-119) is a first-in-class agonist antibody targeting muscle-specific kinase (MuSK), set to enter Phase III for congenital myasthenic syndromes in Q3 2026, with proof-of-concept studies ongoing in ALS and SMA. FB102, the asset argenx would acquire once the Forte Biosciences deal closes, is a first-in-class anti-CD122 monoclonal antibody with positive Phase Ib data reported in vitiligo on July 9, 2026 and in celiac disease, with Phase II celiac data expected in the second half of 2026. FB102 is investigational and is not approved in any territory.

Recent Developments

On July 27, 2026, argenx signed a definitive merger agreement to acquire Forte Biosciences for $77.00 per share in cash, valuing Forte at approximately $2.2 billion. The structure is a cash tender offer followed by a merger, funded entirely from cash on hand, at an 86% premium to Forte's volume-weighted average price since its July 9, 2026 vitiligo data.

The deal has not closed. It requires a majority of Forte's outstanding shares to be tendered and the Hart-Scott-Rodino waiting period to expire or be terminated, and argenx expects it to complete in the third quarter of 2026.

The FDA approved the expanded VYVGART label covering all gMG serotypes on May 8, 2026, making it the first and only treatment approved across anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative patients.

Karen Massey took over as Chief Executive Officer under a transition announced in January 2026 and put to shareholders at the annual general meeting on May 6, 2026, with co-founder Tim Van Hauwermeiren moving to non-executive Director and Chairman. Second-quarter 2026 net sales of $1.5 billion and net profit of $472 million mean argenx is now funding its pipeline expansion from its own trading.

Key Personnel

Karen Massey serves as Chief Executive Officer and Executive Director, having stepped up from Chief Operating Officer under the transition announced in January 2026. Tim Van Hauwermeiren, a co-founder of argenx and its long-serving former chief executive, now serves as non-Executive Director and Chairman. Sandrine Piret-Gérard serves as Chief Commercialization Officer, joining from Gilead's U.S. organization.

Strategic Partnerships

Germany-based logistics group Arvato expanded its European partnership with argenx in June 2025, running direct distribution for the Spanish market from Alcalá de Henares and for the Italian market from its site at Calcinate near Bergamo.

In July 2025, California biotech Unnatural Products entered a strategic multi-target research collaboration with argenx to discover oral macrocyclic peptide drugs against traditionally undruggable targets.

The pending Forte Biosciences merger agreement, signed on July 27, 2026, is the largest of these moves; Goldman Sachs International is financial adviser to argenx and Freshfields LLP is legal counsel.

FAQ Section

argenx is deliberately layering mechanistically distinct assets alongside efgartigimod rather than depending solely on FcRn label expansions for growth. The pending $2.2 billion acquisition of Forte Biosciences would add FB102, an anti-CD122 antibody with a completely different mechanism, reaching into dermatological and gastrointestinal indications. The Immunology Innovation Program is designed to generate at least one new clinical candidate per year, with ten molecules expected to be in clinical development by end of 2026.

The FcRn receptor normally recycles IgG antibodies, extending their half-life; blocking it accelerates IgG degradation and reduces the circulating pathogenic antibodies that drive a wide range of autoimmune conditions. Because the mechanism is upstream of disease-specific targets, the same molecule, efgartigimod, can be investigated across dozens of IgG-mediated indications without reformulation. argenx has described VYVGART as a "pipeline in a product" precisely because the addressable indication set is unusually broad for a single approved therapy.

argenx developed and commercialized the first-in-class FcRn blocker and retains an approved product across three indications and multiple serotypes, a commercial lead its competitors have not yet matched. Its expanded gMG label, granted in May 2026, made VYVGART and VYVGART Hytrulo the only treatments approved for all adult gMG serotypes including triple seronegative patients, a clinically meaningful distinction. The company is also developing next-generation FcRn assets (ARGX-213, ARGX-124) designed for improved half-life and sustained IgG reduction, which suggests it is engineering against its own eventual competition.

FB102 is a first-in-class anti-CD122 monoclonal antibody that targets the IL-2 and IL-15 receptor beta chain, modulating T-cell and NK-cell activity implicated in autoimmune skin and gastrointestinal disease. Forte Biosciences reported positive Phase Ib data in vitiligo on July 9, 2026, and has also demonstrated positive Phase Ib results in celiac disease, with Phase II celiac data expected in the second half of 2026. The $2.2 billion price, an 86% premium to Forte's volume-weighted average price since that July 9 readout, reflects argenx's conviction that early proof-of-concept across two distinct indications is worth paying up for. The asset is still early, registrational trials have not started, and the acquisition itself has not closed.

The pipeline spans neuromuscular disease (myositis via ALKIVIA, multifocal motor neuropathy via EMPASSION, congenital myasthenic syndromes via adimanebart), rheumatology and connective tissue disease (Sjogren's disease via UNITY), nephrology (IgA nephropathy with ARGX-121, delayed graft function with empasiprubart), and, if the Forte deal closes, dermatology and gastroenterology through FB102. Empasiprubart's complement-inhibiting mechanism and adimanebart's MuSK agonism represent entirely distinct biological approaches from the FcRn franchise, deliberately broadening the company's mechanistic base.

argenx is firmly in the commercial stage: it reported $4.15 billion in full-year 2025 product net sales and $838 million in net profit for the first half of 2026, with approximately 19,000 patients on VYVGART globally. With $5.2 billion in cash and financial assets as of June 30, 2026, the company is funding a $929 million first-half R&D spend and the pending $2.2 billion Forte acquisition entirely from its own balance sheet. The next major clinical milestones are ALKIVIA (myositis) topline data in Q3 2026 and EMPASSION (MMN) topline data in Q4 2026.

The merger agreement was signed on July 27, 2026, but the transaction is not complete. argenx is buying Forte through a cash tender offer at $77.00 per share, and closing requires that a majority of Forte's outstanding shares are tendered and that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expires or is terminated. Shares not tendered convert into the right to receive the same $77.00 in cash once a wholly owned argenx subsidiary merges with Forte. There is no financing condition; argenx is paying from cash on hand and expects to close in the third quarter of 2026.

Want to Update your Company's Profile?